GENAISSANCE PHARMACEUTICALS INC
10-Q, EX-27, 2000-11-14
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: GENAISSANCE PHARMACEUTICALS INC, 10-Q, EX-10.4, 2000-11-14
Next: PROVIDENCE CAPITAL X INC, 10QSB, 2000-11-14



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>                     <C>                     <C>
<PERIOD-TYPE>                   12-MOS                   9-MOS                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999             SEP-30-2000             SEP-30-1999
<PERIOD-END>                               DEC-31-1999             SEP-30-2000             SEP-30-1999
<CASH>                                           3,666                  82,895                       0
<SECURITIES>                                         0                  38,386                       0
<RECEIVABLES>                                        0                       0                       0
<ALLOWANCES>                                         0                       0                       0
<INVENTORY>                                          0                       0                       0
<CURRENT-ASSETS>                                 3,872                 122,202                       0
<PP&E>                                               0                       0                       0
<DEPRECIATION>                                       0                       0                       0
<TOTAL-ASSETS>                                  11,514                 151,838                       0
<CURRENT-LIABILITIES>                            3,528                  10,571                       0
<BONDS>                                              0                       0                       0
                           11,247                       0                       0
                                          0                       0                       0
<COMMON>                                             3                      23                       0
<OTHER-SE>                                    (14,835)                 116,768                       0
<TOTAL-LIABILITY-AND-EQUITY>                    11,514                 151,838                       0
<SALES>                                              0                       0                       0
<TOTAL-REVENUES>                                     0                     187                     616
<CGS>                                                0                       0                       0
<TOTAL-COSTS>                                        0                       0                       0
<OTHER-EXPENSES>                                     0                  26,967                   6,424
<LOSS-PROVISION>                                     0                       0                       0
<INTEREST-EXPENSE>                                   0                   1,300                     373
<INCOME-PRETAX>                                      0                (25,433)                 (5,964)
<INCOME-TAX>                                         0                       0                       0
<INCOME-CONTINUING>                                  0                       0                       0
<DISCONTINUED>                                       0                       0                       0
<EXTRAORDINARY>                                      0                       0                       0
<CHANGES>                                            0                       0                       0
<NET-INCOME>                                         0                (81,940)                 (7,531)
<EPS-BASIC>                                          0                 (11.68)                  (2.80)
<EPS-DILUTED>                                        0                       0                       0


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission